Koyfin Home > Directory > Health Care > Acorda Therapeutics > EBITDA / Interest Expenses

Acorda Therapeutics EBITDA / Interest Expenses Chart (ACOR)

Acorda Therapeutics annual/quarterly EBITDA / Interest Expenses from 2010 to 2020. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • Acorda Therapeutics EBITDA / Interest Expenses for the quarter ending June 06, 2020 was $-1m a -196.15% increase of 3m year over year
  • Acorda Therapeutics EBITDA / Interest Expenses for the last 12 months ending June 06, 2020 was $-2m a -89.53% increase of 2m year over year
  • Acorda Therapeutics Annual EBITDA / Interest Expenses for 2019 was $-3m a 253.69% decrease of -8m from 2018
  • Acorda Therapeutics Annual EBITDA / Interest Expenses for 2018 was $5m a -48.73% decrease of -2m from 2017
  • Acorda Therapeutics Annual EBITDA / Interest Expenses for 2017 was $7m a 90.18% increase of 7m from 2016
Other Ratios Metrics:
  • Acorda Therapeutics Total Debt / Capital for the quarter ending December 12, 2018 was $36m a -5.79% decrease of -2m year over year
  • Acorda Therapeutics Other Liabilities for the quarter ending December 12, 2018 was $204m a 10.59% increase of 22m year over year
  • Acorda Therapeutics Total Debt / Equity for the quarter ending December 12, 2018 was $56m a -9.35% decrease of -5m year over year
View Chart On Koyfin

Quarterly ACOR EBITDA / Interest Expenses Data

06/2020$-1m
03/2020$-3m
12/2019$0m
09/2019$-4m
06/2019$-4m
03/2019$-4m
12/2018$-3m
09/2018$10m
06/2018$10m
03/2018$2m

Annual ACOR EBITDA / Interest Expenses Data

2019$-3m
2018$5m
2017$7m
2016$1m
2015$4m
2014$6m
2013$18m
2012$16m
2011$15m
2010$-1m